Business · 1 sources covering this

Solid debut! Molbio Diagnostics shares list at 21% premium over IPO price

The listing beat expectations as signalled by the grey market premium (GMP). Ahead of its debut today, Molbio Diagnostics IPO GMP was ₹120, suggesting 15 per cent listing pop.

Share:WhatsApp X Reddit Facebook LinkedIn

Coverage spectrum

0 L · 1 C · 0 R

How 1 sources are covering this

Business StandardCenter·1h ago
Solid debut! Molbio Diagnostics shares list at 21% premium over IPO price
The listing beat expectations as signalled by the grey market premium (GMP). Ahead of its debut today, Molbio Diagnostics IPO GMP was ₹120, suggesting 15 per cent listing pop.
Read at Business Standard →

Embed this bias spectrum on your site

Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.

<iframe
  src="https://hindustansphere.com/embed/cluster/8e87919e475b65ef5ec6a729aea99d9f3c4a100b"
  width="100%" height="320"
  style="border:0;max-width:680px"
  loading="lazy"
  title="Solid debut! Molbio Diagnostics shares list at 21% premium over IPO price"></iframe>

Solid debut! Molbio Diagnostics shares list at 21% premium over IPO price

How 1 sources are covering this

Solid debut! Molbio Diagnostics shares list at 21% premium over IPO price

More from Business

Price taker to price setter: India’s commodity derivatives market

Delhi Master Plan 2047: How housing, transport and land use may change

NRI life insurance: Buy in India or abroad?

India seaplanes get electrifying push

Reader

Trust & legal

Across the network